Allogene Therapeutics Inc logo

ALLO - Allogene Therapeutics Inc Share Price

$19.92 -0.3  -1.6%

Last Trade - 27/03/20

Sector
Healthcare
Size
Mid Cap
Market Cap £2.00bn
Enterprise Value £1.57bn
Revenue £n/a
Position in Universe 1381st / 6324
Bullish
Bearish
Unlock ALLO Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ALLO Revenue Unlock ALLO Revenue

Net Income

ALLO Net Income Unlock ALLO Revenue

Normalised EPS

ALLO Normalised EPS Unlock ALLO Revenue

PE Ratio Range

ALLO PE Ratio Range Unlock ALLO Revenue

Dividend Yield Range

ALLO Dividend Yield Range Unlock ALLO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ALLO EPS Forecasts Unlock ALLO Revenue
Profile Summary

Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated November 30, 2017
Public Since October 11, 2018
No. of Shareholders: 74
No. of Employees: 205
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 124,906,945
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ALLO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ALLO
Upcoming Events for ALLO
Similar to ALLO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.